Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia
Summary. Aim: Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a...
Gespeichert in:
| Datum: | 2023 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | English |
| Veröffentlicht: |
PH Akademperiodyka
2023
|
| Schlagworte: | |
| Online Zugang: | https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-15 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Назва журналу: | Experimental Oncology |
Institution
Experimental Oncology| id |
oai:ojs2.ex.aqua-time.com.ua:article-225 |
|---|---|
| record_format |
ojs |
| institution |
Experimental Oncology |
| baseUrl_str |
|
| datestamp_date |
2023-10-11T16:42:06Z |
| collection |
OJS |
| language |
English |
| topic |
elevated total B12 myeloid leukemia oncohematological diseases |
| spellingShingle |
elevated total B12 myeloid leukemia oncohematological diseases Gavars, D. Perminov, D. Tauckels, E. Lindenberga, I. Auce, A. Lejniece, S. Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| topic_facet |
elevated total B12 myeloid leukemia oncohematological diseases elevated total B12 myeloid leukemia oncohematological diseases |
| format |
Article |
| author |
Gavars, D. Perminov, D. Tauckels, E. Lindenberga, I. Auce, A. Lejniece, S. |
| author_facet |
Gavars, D. Perminov, D. Tauckels, E. Lindenberga, I. Auce, A. Lejniece, S. |
| author_sort |
Gavars, D. |
| title |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| title_short |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| title_full |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| title_fullStr |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| title_full_unstemmed |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| title_sort |
association of elevated vitamin b12 with oncohematological diseases in a cohort of 79,524 patients from latvia |
| title_alt |
Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia |
| description |
Summary. Aim: Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients. Materials and Methods: Overall Latvian population representative data on B12 testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B12 results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerular filtration rate (< 45 mL/min/1.73 m2). As a control group, individuals with normal B12 level and any oncologic diagnosis (solid cancer or hematological malignancies) were selected. Results: After application of step-by-step exclusion filters, 1,373 patients were left with significantly increased level of plasma B12 (> 1,700 pg/mL). Odds ratios for oncohematological diseases in total and myeloid leukemia (including acute, chronic and unspecified) in patient group with elevated B12 were found to be 6.0 (95% CI 4.7–7.6; p < 0.0001) and 19.2 (95% CI 13.1–28.0; p <0.0001), respectively, as compared to the control group. Conclusion: Elevated total B12 could be considered as a potential marker for oncohematological disorders. |
| publisher |
PH Akademperiodyka |
| publishDate |
2023 |
| url |
https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-15 |
| work_keys_str_mv |
AT gavarsd associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia AT perminovd associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia AT tauckelse associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia AT lindenbergai associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia AT aucea associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia AT lejnieces associationofelevatedvitaminb12withoncohematologicaldiseasesinacohortof79524patientsfromlatvia |
| first_indexed |
2025-07-17T12:16:46Z |
| last_indexed |
2025-07-17T12:16:46Z |
| _version_ |
1837896414229692416 |
| spelling |
oai:ojs2.ex.aqua-time.com.ua:article-2252023-10-11T16:42:06Z Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia Gavars, D. Perminov, D. Tauckels, E. Lindenberga, I. Auce, A. Lejniece, S. elevated total B12, myeloid leukemia, oncohematological diseases elevated total B12, myeloid leukemia, oncohematological diseases Summary. Aim: Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients. Materials and Methods: Overall Latvian population representative data on B12 testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B12 results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerular filtration rate (< 45 mL/min/1.73 m2). As a control group, individuals with normal B12 level and any oncologic diagnosis (solid cancer or hematological malignancies) were selected. Results: After application of step-by-step exclusion filters, 1,373 patients were left with significantly increased level of plasma B12 (> 1,700 pg/mL). Odds ratios for oncohematological diseases in total and myeloid leukemia (including acute, chronic and unspecified) in patient group with elevated B12 were found to be 6.0 (95% CI 4.7–7.6; p < 0.0001) and 19.2 (95% CI 13.1–28.0; p <0.0001), respectively, as compared to the control group. Conclusion: Elevated total B12 could be considered as a potential marker for oncohematological disorders. Summary. Aim: Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients. Materials and Methods: Overall Latvian population representative data on B12 testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B12 results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerular filtration rate (< 45 mL/min/1.73 m2). As a control group, individuals with normal B12 level and any oncologic diagnosis (solid cancer or hematological malignancies) were selected. Results: After application of step-by-step exclusion filters, 1,373 patients were left with significantly increased level of plasma B12 (> 1,700 pg/mL). Odds ratios for oncohematological diseases in total and myeloid leukemia (including acute, chronic and unspecified) in patient group with elevated B12 were found to be 6.0 (95% CI 4.7–7.6; p < 0.0001) and 19.2 (95% CI 13.1–28.0; p <0.0001), respectively, as compared to the control group. Conclusion: Elevated total B12 could be considered as a potential marker for oncohematological disorders. PH Akademperiodyka 2023-06-02 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-15 10.32471/exp-oncology.2312-8852.vol-41-no-4.13930 Experimental Oncology; Vol. 41 No. 4 (2019): Experimental Oncology; 354-362 Експериментальна онкологія; Том 41 № 4 (2019): Експериментальна онкологія; 354-362 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-41-no-4 en https://exp-oncology.com.ua/index.php/Exp/article/view/2019-4-15/2019-4-15 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/ |